Tumor-derived interleukin-6 was demonstrated as an underlying mechanism of thrombocytosis in cancer [22], and serum interleukin-6 levels were shown to be 2.4-fold higher in OS than in controls [27, 28]. This evidence concerns the gene IL6 and thrombocytosis disease.